Aktuelle (System-)Therapiestandards

Malignes Melanom

This is a preview of subscription content, access via your institution.

Literatur

  1. 1.

    AWMF, Deutsche Krebsgesellschaft, Deutsche Krebshilfe. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms, Version 3.1. 2018; AWMF-Registernr. 032/024OL

  2. 2.

    Faries MB et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017;376(23):2211-22

  3. 3.

    Leiter U et al. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. J Clin Oncol. 2019;37(32):3000-8

  4. 4.

    Grundmann O et al. Sensitivity of Salivary Glands to Radiation from Animal Models to Therapies. J Dent Res. 2009;88(10):894-903

  5. 5.

    Saiag P et al. Efficacy of hypofractionated radiotherapy (RT) in melanoma patients who failed anti PD-1 monotherapy: Assessing the abscopal effect. Int J Cancer. 2020;147(6):1707-14

  6. 6.

    Tarhini AA et al. IFN-α in the treatment of melanoma. J Immunol. 2012; 189: 3789-93

  7. 7.

    Ives NJ et al. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017; 82:171-83

  8. 8.

    Eggermont AM et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522-30

  9. 9.

    Weber J et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824-35

  10. 10.

    Eggermont AMM et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018;378(19):1789-801

  11. 11.

    Eggermont AM et al. EORTC 1325-MG/ Keynote 054: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results at three-year median follow up. J Clin Oncol. 2020;38(suppl_15):Abstr 10000

  12. 12.

    Majo M et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018;19(4): 510-20

  13. 13.

    Long GV et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017; 377(19):1813-23

  14. 14.

    Hausschild A et al. Long- term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAFV600-mutant melanoma: Five-year analysis of COMBI-AD. J Clin Oncol. 2020; 38(suppl_15):Abstr 10001

  15. 15.

    Robert C et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372(4):320-30

  16. 16.

    Schachter J et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853-62

  17. 17.

    Wolchok JD et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017; 377(14):1345-56

  18. 18.

    Ascierto PA et al. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol. 2019;5(2):187-94

  19. 19.

    Robert C et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019; 20(9):1239-51

  20. 20.

    Larkin J et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Eng J Med. 2019; 381(16):1535-46

  21. 21.

    Long GV et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631-9

  22. 22.

    Robert C et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-9

  23. 23.

    Ascierto PA et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)- mutant melanoma (coBRIM): updated efficacy results from a randomised, doubleblind, phase 3 trial. Lancet Oncol. 2016; 17(9):1248-60

  24. 24.

    Dummer R et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315-27

  25. 25.

    Robert C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26

  26. 26.

    Andtbacka RHI et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015;33(25):2780-8

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dr. med.  Lucia Peeken.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Peeken, L., Schultz, E. & Debus, D. Malignes Melanom . Im Fokus Onkologie 24, 23–27 (2021). https://doi.org/10.1007/s15015-020-3353-7

Download citation